Adenosine-A2A Receptor Pathway in Cancer Immunotherapy

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Adenosine A2A receptors (A2AR) are GPCRs found on immune cells, crucial for regulating immune responses.
• The adenosine-A2AR pathway normally protects tissues but is exploited by tumors to suppress anti-tumor immunity.

Purpose of the Study:

• To review the role of the adenosine-A2AR pathway in the tumor microenvironment.
• To summarize recent advancements in A2AR-targeted cancer therapies.

Main Methods:

• Literature review of animal experiments and clinical trials on A2AR blockade in cancer.
• Analysis of studies combining A2AR inhibitors with immunotherapies like CAR T cells.

Main Results:

• Solid tumors accumulate adenosine, activating A2AR and inhibiting immune cell function, promoting immune escape.
• Blocking the adenosine-A2AR pathway demonstrates anti-tumor effects across various solid tumors.
• Combination therapy of A2AR blockade with CAR T cells shows promising enhanced anti-tumor efficacy.

Conclusions:

• The adenosine-A2AR pathway is a significant target in the tumor microenvironment for cancer immunotherapy.
• Targeting A2AR presents a viable strategy for developing novel cancer treatments, particularly in combination therapies.